Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Modification of Protein-Nanoparticle Complexes for Delivery of Nucleic Acid Therapeutics
EF 2018-19
Résumé
Improved nucleic acid therapy targeting towards cancer cells in vivo would improve efficacy of treatment, reduce off-target effects and subsequently, reduce toxicity. One technique that may improve targeting is the use of nanoparticles as carriers for therapeutics. Studies have shown that nanoparticles can have positive effects on circulation and biodistribution, however few are currently employed as clinical treatments. By developing a nanoparticle that binds to human serum albumin (HSA) we hope to develop a novel therapeutic technique for treatment of different diseases via the implementation of siRNA based gene silencing. Previous work in the Sleiman lab has shown that rigid nanocube scaffolds can be made with control over the spatial orientation of ligands around the structure. One such ligand that has been conjugated to nanostructures is D1, a molecule made of monomeric alkane chains shown to bind HSA and may hold promise as a method to increase viability of nucleic acid therapeutics in vivo. A D1-fluorophore-siRNA strand will be made via solid phase phosphoramidite chemistry with the siRNA strand silencing luciferase. This molecule will be bound to nanostructures through Watson-Crick base pairing and purified using gel electrophoresis and reverse phase chromatography. The binding of the nanoparticle to HSA will be analyzed using gel electrophoresis and surface plasmon resonance. The tumour penetration, internalization and silencing of luciferase will be tested in cell models to probe the efficacy of this method for potential therapeutic delivery. Future studies may look at other factors such as biodistribution and tumor accumulation or the differences caused by changes in geometry via addition of D1 to other DNA nanostructures made in the Sleiman lab.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406325
Name
Asohan Jathavan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Modification of Protein-Nanoparticle Complexes for Delivery of Nucleic Acid Therapeutics
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Dna Nanoparticles; Dna Nanostructures; Drug Delivery; Human Serum Albumin; Nucleic Acid Therapeutics; Phosphoramidite Chemistry; Protein Corona; Solid Phase Synthesis
Abstract
Improved nucleic acid therapy targeting towards cancer cells in vivo would improve efficacy of treatment, reduce off-target effects and subsequently, reduce toxicity. One technique that may improve targeting is the use of nanoparticles as carriers for therapeutics. Studies have shown that nanoparticles can have positive effects on circulation and biodistribution, however few are currently employed as clinical treatments. By developing a nanoparticle that binds to human serum albumin (HSA) we hope to develop a novel therapeutic technique for treatment of different diseases via the implementation of siRNA based gene silencing. Previous work in the Sleiman lab has shown that rigid nanocube scaffolds can be made with control over the spatial orientation of ligands around the structure. One such ligand that has been conjugated to nanostructures is D1, a molecule made of monomeric alkane chains shown to bind HSA and may hold promise as a method to increase viability of nucleic acid therapeutics in vivo. A D1-fluorophore-siRNA strand will be made via solid phase phosphoramidite chemistry with the siRNA strand silencing luciferase. This molecule will be bound to nanostructures through Watson-Crick base pairing and purified using gel electrophoresis and reverse phase chromatography. The binding of the nanoparticle to HSA will be analyzed using gel electrophoresis and surface plasmon resonance. The tumour penetration, internalization and silencing of luciferase will be tested in cell models to probe the efficacy of this method for potential therapeutic delivery. Future studies may look at other factors such as biodistribution and tumor accumulation or the differences caused by changes in geometry via addition of D1 to other DNA nanostructures made in the Sleiman lab.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Asohan, Jathavan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~